Abstract: Fogo selvagem or endemic pemphigus foliaceus is an autoimmune acantholytic anti-cadherin bullous disease that primarily affects seborrheic areas, which might disseminate. Brazil has the world's largest number of patients, mainly in the Central-West region, but the disease has also been reported in other South American countries. It affects young people and adults who have been exposed to rural areas, with occurrence of familial cases. Anti-desmoglein-1 autoantibodies are directed against desmosomal structures, with loss of adhesion of the upper layers of the epidermis, causing superficial blisters. The etiology is multifactorial and includes genetic, immune, and environmental factors, highlighting hematophagous insect bites; drug-related factors are occasionally involved. Flaccid blisters readily rupture to yield erosive-crusty lesions that sometimes resemble seborrheic dermatitis, actinic keratosis, and chronic cutaneous lupus erythematosus. The clinical presentation varies from localized to disseminated lesions. Clinical suspicion should be confirmed with histopathological and immunofluorescence tests, among others. The progression is usually chronic, and therapy varies according to clinical presentation, but generally requires systemic corticosteroid therapy associated with adjuvant immunosuppressive treatment to decrease the adverse effects of corticosteroids. Once the disease is under control, many patients remain stable on low-dose medication, and a significant proportion achieve remission.
INTRODUCTION
The term pemphigus refers to a group of cutaneous diseases clinically characterized by the manifestation of vesicle-blisters and/ or erosions of the skin and/or mucous membranes. The disease is characterized histologically by the presence of acantholysis, that is, the separation of the keratinocytes resulting in the formation of intraepidermal cleavage, and/or immunologically by the detection of autoantibodies against intercellular adhesion molecules called desmogleins (Dsg), which are transmembrane desmosomal glycoproteins. 1, 2 Among the pemphigus presentations, we highlight pemphigus foliaceus (PF), with exclusive cutaneous involvement due to the production of antibodies against desmoglein 1 (Dsg1), and pemphigus vulgaris (PV), which manifests in two forms: the mucous type, due to the synthesis of antibodies against desmoglein 3, and the mucocutaneous type, with concomitant production of anti-Dsg1. 2, 3 Table 1 provides a summary of the clinical and laboratory findings of the pemphigus group and its variants. 4 The endemic variant of PF is known as fogo selvagem (FS), which means "wildfire" in the Portuguese language. FS shares clinical, histopathological, and immunological characteristics with classical PF and is distinguished from it by epidemiological aspects, namely higher frequency in children and young adults in rural areas and in regions geographically known by high incidence of FS, besides the presence of familial cases. The symptoms resemble those of burn injuries. Most FS patients live in rural areas, which explains how the disease came to be known as "fogo selvagem" or "wildfire", a term that has been established in the medical literature. [4] [5] [6] pemphygodes" was applied in the 17 th century to various bullous diseases, but De Sauvages called pemphigus a vesiculobullous disease. 13 In 1777, McBride was the first author to describe pemphigus vulgaris, with the term morbus vesicularis. 14 Finally, pemphigus foliaceus was first described in 1844 by Pierre Louis Alphée Cazenave. 15 Pemphigus brasiliensis was mentioned for the first time by
François Boissier de Sauvages (1768) in his work Nosologia Methodica, referring to the observation made by Father Bougeant, who worked as a missionary in Brazil in 1730. In 1948, however, after a critical review, Silva concluded that it was herpes zoster. 16 The first FS patient diagnosed in Brazil was reported by Caramuru PaesLeme in 1903, causing confusion with the bullous variant of tinea corporis, that is, tinea imbricata or Tokelau. Gualberto, in 1912, cor- rected this diagnosis when he discovered that the description was similar to the PF of Cazenave. 17 The modern history of pemphigus began with Heinrich Auspitz (1881), who described the histological findings of a bullous lesion called acantholysis. 15 The diagnostic maneuver applied to pemphigus (detachment of the skin by pressing it in the vicinity of a lesion) was suggested by Nikolsky in 1896. 18 The first description of FS histology was performed by a Brazilian dermatologist, João Paulo Vieira, who published the study entitled "Contribution to the Study of Pemphigus in the State of São Paulo" in 1937. 19 Civatte, in 1943, differentiated PV from PF based on histology, and in 1953
Lever separated bullous pemphigoid from the pemphigus group based on clinical and histopathological findings. 20 In 1964, Beutner and Jordon described pemphigus antibodies in patients with PV. 8 In 1968, antibodies were detected in the intercellular space in patients with FS, 21 and in 1982, the pathogenic nature of these autoantibodies was demonstrated in an animal model (BALB/c mice) by Anhalt et al. 22 Some studies have analyzed the historical migration of FS in (Table 1) . Comparative immunochemical studies using anti-Dsg1 monoclonal and polyclonal antibodies found that the 160 kDa protein recognized in the serum of FS patients was Dsg1.
Molecular cloning of cDNA with PF and PV antigens indicated that both molecules (Dsg1 and Dsg3) are members of the cadherin supergene family. 9, 36, 37 Cadherins belong to the family of calcium-dependent cell adhesion molecules that play an important role in the formation and maintenance of complex tissue integrity. Based on sequential similarity, cadherins have two main subgroups, the classical cadherins (e.g., -E-, -P, -N-cadherins) and the desmosomal cadherins (desmogleins and desmocollins). All members of the cadherin family contain repeat sequences of amino acids with calcium binders in the FIgure 1: Molecular homology between desmoglein 1*, desmoglein 3 and E-cadherin. Desmogleins 1 and 3 are desmosomal transmembrane proteins sharing the same cadherin-like domain structure of E-cadherin. The EC1-EC2 domains of Dsg1 are recognized by pathogenic autoantibodies of FS patients, whereas Dsg3 is bound by autoantibodies from pemphigus vulgaris patients. Autoantibodies against E-cadherin have also been described in mucocutaneous PV, PF, and FS. 
FS pathogenic autoantibodies
The main characteristic of pemphigus is the detection of IgG autoantibodies in the intercellular spaces of the epidermis, demonstrated by immunofluorescence. 7, 20 Pemphigus antibodies found in the serum of patients play a primary pathogenic role in the induction of loss of cell adhesion between keratinocytes and subsequent formation of vesicle-blisters. 3, 27, 40 The binding between IgG and Dsg1 leads to disruption of the desmosomes located in the upper portion of the epidermis and loss of adhesion between the keratinocytes, a process known as acantholysis. 43 The location of acantholysis in pemphigus can be explained by compensation theory, according to which the level of cleavage varies according to the autoantibodies and their distribution in the epidermis. A significantly higher frequency of anti-Dsg3 antibodies has been found (p<0.001) in healthy controls from endemic areas for FS (36%) compared to surrounding areas (6%), which supports the hypothesis that the FS antibody responds to an environmental factor in the endemic area, and that the population at risk of developing FS may also be at risk of developing the endemic form of PV, as already published. antibodies are also present. In experimental models for FS conducted in mice, in addition to IgG4, F(ab')2 and IgG Fab fragments were also found to be pathogenic. Figure 3) . 47, 48 Acantholysis is mediated by both extracellular (signaling-independent) and intracellular (signaling-dependent) mecha- undergoing treatment increased serum IL-6 and TNF-a levels when compared to healthy controls. In endemic and non-endemic PF cases, higher levels of IL-6 and TNF-a were found in patient biopsies. Neonatal pemphigus vulgaris is more frequent than neonatal pemphigus foliaceus, since the presence of desmoglein 3 predominates in the skin of the newborn rather than Dsg1. 61 The lead author of this paper diagnosed neonatal fogo selvagem in the infant of a mother with disseminated FS and high anti-Dsg1 autoantibody titers (in press). 
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Interleukins in Fogo Selvagem
DIFFERENTIAL DIAGNOSIS
ELISA (enzyme-linked immunosorbent assay):
the patient's serum is examined using recombinant desmoglein-1 as the antigen source, which has a high level of sensitivity (greater than 90%) and specificity, superior to IIF. It can also be used for the patient's follow-up.
Additional serological tests may be indicated, such as immunoprecipitation and immunoblotting, but they are limited to academic studies because of their complexity.
In summary, the laboratory evaluation to confirm the clinical diagnosis of pemphigus or any other autoimmune bullous disease includes: biopsy of injured skin (and/or mucosa if pemphigus vulgaris) for routine HE staining at the edge of the blister or erosion, with a 4mm punch; perilesional skin biopsy for DIF; and/or serum sample for ELISA and/or IIF.
COMPLICATIONS
In extensive forms, alteration of the skin barrier may result in protein and fluid loss, electrolyte imbalance, accelerated catabolism, and increased risk of local and systemic infections. The immunosuppressive treatment used in patients with severe onset FS may predispose to opportunistic infections, sometimes fatal.
TREATMENT
The treatment goal is to induce complete remission of the disease, minimizing the drug-related adverse effects. 30, [64] [65] [66] [67] Risk factors and comorbidities must be identified, in addition to evaluating prognosis according to the patient's age and general condition.
Regarding indications for hospital admission, the patient's clinical condition should be assessed using the Karnovsky index, in which a value of 100% refers to a normal person, with no evidence of disease; hospitalization is indicated when the index is 50% or less (50% refers to a patient requiring considerable assistance, often medical/ specialized care, and 40% refers to an incapacitated patient requiring specialized care and assistance). To decide on the best treatment regimen in FS, it is recommended to determine the extent of the disease. A practical approach is to assess the body surface area with active FS lesions, in which mild disease affects up to 1%, moderate disease up to 10%, and severe disease over 10% of the skin area, with 1% representing the sum of FS lesion areas that correspond approximately to the palmar area of the hands. Some dermatology departments have protocols to verify the extent and severity of the lesions using the Pemphigus Area and Activity Score (PAAS) and Autoimmune Bullous Skin Disorder Intensity Score (ABSIS). 69, 70 Before treatment begins, a complete blood count, creatinine, serum sodium and potassium, alanine transaminase (ALT), aspartate transaminase (AST), gamma glutamyl transferase, alkaline phosphatase, serum proteins, blood glucose, hepatitis B and C serology, HIV serology, and chest radiography should be ordered. Additional recommendations are to rule out IgA deficiency before administering IV immunoglobulin; thiopurine methyltransferase enzyme activity before azathioprine; abdominal ultrasound (optional), tuberculin skin test, or quantiferon-TB if there is high risk of TB; glucose-6-phosphate dehydrogenase deficiency, bilirubin levels, and reticulocyte parameters before dapsone; and β-HCG test to rule out pregnancy, bone mineral density before corticosteroid therapy, and ophthalmological evaluation to rule out glaucoma and cataract. Besides coproparasitology, prophylaxis of strongyloidiasis is recommended, as well as antibiotic therapy whenever pyoderma is present.
In localized forms with a limited number of lesions (up to 1% of body surface area), topical corticosteroids (from moderate to high potency), intralesional corticosteroids (triamcinolone acetonide 2-3mg/ml) or calcineurin inhibitors are used. Associated with topical therapy, dapsone 50-100mg a day may be prescribed. In some patients, low-dose prednisone (0.25mg/kg/d) can be prescribed.
Systemic corticosteroid (prednisone/prednisolone) is prescribed at a dose of 0.5mg/kg/day whenever topical treatment is insufficient to control disease activity, or if there is worsening of the skin condition with an increase in the number of lesions. In severe disseminated forms, the dose is 1mg/kg/day of prednisone or prednisolone. Systemic corticosteroid therapy is still the most widely used and recognized treatment option. Equivalent doses of triamcinolone may be administered in FS-resistant patients.
Considering that prolonged therapy with high-dose systemic corticosteroids can lead to serious or even fatal adverse effects, the early association of corticosteroid-sparing drugs (adjuvants) such as methotrexate, azathioprine, and mycophenolate mofetil is important in patients with disseminated disease. According to recent publications, the best combination would be deflazacort with azathioprine. Among the factors to consider in the choice of an adjuvant therapy are the availability, cost, and side effects of the medication.
Immunosuppressants (first-line adjuvant therapy):
Optimal adjuvants are azathioprine and mycophenolate mofetil, which have known corticoid-sparing effects. Azathioprine Methotrexate (MTX) is an interesting option due to its low cost and easy availability, but it is hepatotoxic. It is used at a dose of 7.5 to 25mg/week on 1 day or 2 consecutive days. After 24 hours, folic acid at a dose of 5mg must be prescribed. Alcohol, sulfonamides, and allopurinol must not be used concurrently.
For mild forms, dapsone (DDS)100mg/d or up to 1.5mg/ kg/d can be used, since it also has a corticosteroid-sparing effect;
however, glucose-6-phosphate dehydrogenase (G6PD) activity should be verified first. Considering that pemphigus is an antibody-mediated disease, the use of dapsone is controversial. According to study by a group from Philadelphia, USA, dapsone is ineffective in this setting.
Cyclophosphamide at a dose of 500mg IV bolus or 2 mg/ kg/d has a corticosteroid-sparing effect, but the possibility of sterility, hemorrhagic cystitis, and secondary malignant neoplasm should be considered. 
Newer Relevant Therapies
CLINICAL AND LABORATORY FOLLOW-UP
Maintenance after the consolidation phase: progressive corticosteroid (CS) reduction after disease control or by the end of the consolidation phase should be established, decreasing the CS dose by around 25% every 2 weeks until the dose of 20 mg per day is reached, after which the CS dose can be tapered further. If more than three lesions appear, the previous dose should be applied. When relapse occurs, the dose of the two previous phases should be applied.
If the cutaneous lesions fail to stabilize within 2 weeks, the initial dose should be prescribed. In case the therapy is already combined with an immunosuppressant, the latter should be replaced, or IVIg, immunoadsorption, or rituximab should be used. High levels of anti-Dsg1 ELISA indicate the possibility of cutaneous relapses.
Clinical and laboratory follow-up: Clinical reassessment of the skin and mucous membranes should be performed every 2 weeks and then monthly after the disease is controlled. The following adverse effects should be investigated: diabetes mellitus, systemic arterial hypertension, and cardiac failure due to steroid therapy; respiratory distress, anemia, and hepatitis due to DDS and MTX; respiratory infections and hepatitis due to CS and immunosuppressants; mental disorders due to CS; myopathy, osteoporosis, avascular bone necrosis, glaucoma, and cataract due to CS; and hematological abnormalities due to immunosuppressive therapy.
Vaccination:
The use of adjuvant immunosuppressants and rituximab contraindicate live virus vaccination. 
Regarding immunological tests in FS:
a) Indirect immunofluorescence has high sensitivity and specificity. b) Direct immunofluorescence is the gold standard and is performed on a biopsy of apparently normal skin close to the lesion. c) Recombinant desmoglein ELISA has high sensitivity and lower specificity than indirect immunofluorescence. d) All of the above are true. 
